U.S. Industrial REITs Stock News

Picking what to do with Trip.com Group stock is a classic investor’s puzzle. Is it time to hold, buy, or wait? The last year has been especially interesting. Shares are up over 50% in the past 12 months and have more than doubled if you stretch out to three or five years. Even with some recent bumps and the broader market’s volatility, Trip.com’s stock is up about 5% in the past month and over 2% in the last quarter. Still, the stock price has dipped year-to-date, which some see as just a...

Cirrus Logic recently announced an expanded collaboration with GlobalFoundries to jointly develop and commercialize next-generation BCD process and Gallium Nitride (GaN) chip technologies, with manufacturing capabilities in both the U.S. and overseas. This initiative aims to strengthen Cirrus Logic's mixed-signal product portfolio and support more resilient, geographically diverse semiconductor supply chains for customers in sectors such as smartphones, vehicles, and industrial...

Thinking about what to do with your Corning stock? You are not alone. Whether you are watching the ticker with cautious optimism or weighing up that next buy-and-hold move, there is plenty to unpack beneath Corning’s recent performance. The stock has posted a total return of over 61% in the past year, with major upward momentum, especially in the past three months, where it surged more than 34%. Year-to-date, Corning has climbed almost 39%, outpacing many other tech-adjacent companies. All...

NRG Energy (NRG) has caught the eye of investors this week after a sharp price reversal. The company’s stock, which cruised higher early this year, has cooled significantly in recent sessions. This has prompted a fresh round of questions about what comes next. While no major announcement or event appears to have caused the slide, the sudden shift is drawing attention to the underlying fundamentals and whether market sentiment is now overstating future risks or pricing in a period of slower...

If you’ve been keeping an eye on BeOne Medicines (ONC), the new approval from the European Commission may have caught your attention. The regulators just greenlit a film-coated tablet version of BRUKINSA, the company’s flagship treatment, designed to cut patients’ daily pill burden in half and make the experience less daunting. This is not a groundbreaking new indication. However, it could make a real difference in patient adherence, which could influence sales momentum across Europe. It is...

CAVA Group, Inc. ( NYSE:CAVA ) shareholders won't be pleased to see that the share price has had a very rough month...

Apollo Global Management (APO) has slipped just under 1% today, catching the eye of investors who may be wondering if the price dip is a signal or just market noise. While there is no major event making headlines, the move has put fresh focus on where the stock stands after a year marked by shifts in the broader financial sector. These kinds of quiet price moves sometimes invite even more scrutiny, since there is no concrete news to anchor them. Looking at the bigger picture, Apollo Global...

There wouldn't be many who think Lanvin Group Holdings Limited's ( NYSE:LANV ) price-to-sales (or "P/S") ratio of 0.6x...

Earlier this month, Tilray Brands expanded its hemp-derived Delta-9 THC beverage portfolio by launching new 10mg format drinks under the Fizzy Jane's and Happy Flower brands, now available online and across retail markets in 10 states. This development marks a significant step for Tilray Brands into higher-dosage beverage offerings, broadening consumer choice and expanding distribution reach in the U.S. hemp beverage category. We'll explore how the entry into the 10mg THC beverage segment...

Earlier this week, Exponent reported revenues that narrowly exceeded analyst expectations but issued revenue guidance for the coming quarter that landed just below forecasts. This cautious outlook, and the company’s persistently high price-to-earnings ratio despite tepid earnings growth, has drawn attention to concerns about the sustainability of Exponent’s valuation given current performance trends. We'll explore how Exponent's softer revenue guidance and muted growth outlook may reshape...

If you are wrestling with what to do about W.W. Grainger stock right now, you are not alone. Investors have watched Grainger’s shares move sideways and then downward lately, with the price dropping slightly over the past month and a pullback of over 7% in the last 90 days. Yet, when viewed from a longer-term perspective, the story brightens. The stock has delivered a solid 2.6% total return over the past year and has more than doubled over five years. Clearly, this is not a sleepy industrial...

Ares Management (ARES) has caught investor attention again this week, though not for a specific breaking event or dramatic headline. Instead, the stock’s recent moves have many asking themselves whether this quiet period is actually a signal. Perhaps the market is just taking a breather before its next decisive step. For long-term shareholders and those watching from the sidelines, it raises that ever-present question: are we missing something right in front of us? If you zoom out, Ares...

On August 20, 2025, AeroVironment announced the successful delivery and integration of its new P550 small Unmanned Aircraft Systems to the U.S. Army as part of the Long-Range Reconnaissance program, accompanied by comprehensive operator training and support for rapid deployment. This marks a foundational step in the U.S. Army's adoption of modular, AI-enabled UAS platforms, which offer adaptability and long-term upgrade potential for evolving defense needs. We’ll examine how the successful...

Fluence Energy, Inc. ( NASDAQ:FLNC ) shares have retraced a considerable 33% in the last month, reversing a fair amount...

The recent surge in Charles Schwab (SCHW) shares might have caught your eye, especially if you’re wondering whether it’s a fleeting bounce or something more. There hasn’t been a single headline-grabbing event lighting up the news feed. However, the quiet momentum in Schwab’s stock has fueled plenty of back-and-forth among investors. It’s the kind of move that doesn’t demand urgency but definitely calls for a closer look at what might be unfolding beneath the surface. Stepping back, Schwab’s...

Recently, SLM reported that its short percent of float increased by 18.42% since the previous update, with 8.78 million shares now sold short, representing 4.95% of its available trading shares and an average of 3.84 days to cover these positions based on trading volume. This shift suggests traders are increasingly expecting downward movement in SLM's share price, which can influence investor sentiment and trading behavior. We'll explore how the recent rise in short interest could influence...

If you have been watching Elevance Health (ELV) lately, the stock’s recent slide might pique your curiosity. Shares have drifted lower, closing just under $310, and while there is no single headline driving this move, the change in direction comes as investors weigh the company’s longer-term prospects against current performance. Even with steady revenue and net income growth in the past year, the market’s sentiment appears to be shifting. Looking beyond this month’s nearly 10% gain, Elevance...

Key Insights Significantly high institutional ownership implies AppFolio's stock price is sensitive to their trading...

If you are sitting on the fence about what to do with Parker-Hannifin stock, you are not alone. After a string of strong performances over the past year, many investors are trying to decide whether PH still has room to run, or if it is time to take some profits off the table. The past 12 months have treated shareholders well, with a total return of 26.1%. Even more impressive, the stock has more than doubled over the last three years, rewarding long-term holders who believed in the company's...

Thinking about what to do with Williams-Sonoma stock? You are not alone. Even seasoned investors have been keeping a closer eye on WSM, especially after the impressive run over the last year. The stock’s recent performance tells quite the story. It is up roughly 53% over the past twelve months and has more than tripled over the past five years. That kind of growth is hard to ignore, and it has left many wondering whether Williams-Sonoma is still a buy or if it is time to lock in gains. Over...

After Dole (NYSE:DOLE) released its second quarter results, investors found themselves with plenty to digest. The company topped expectations on both revenue and adjusted profit, driven mainly by growth in its Diversified Fresh Produce and Fresh Fruit segments. Management’s decision to complete the sale of the Fresh Vegetable division also signals a clearer focus on areas where Dole sees the highest returns. Additionally, the push toward debt reduction reflects a more cautious, long-term...

Thinking about what to do with Arista Networks stock? You are not alone. As the tech landscape keeps shifting, ANET has caught the eye of many investors who are weighing growth potential against already hefty price gains. Over the past year, Arista Networks has delivered a remarkable 50% total return, with gains stacking up to more than 800% over the last five years. These numbers are enough to make anyone sit up and wonder whether the ride is just getting started or if this rocket ship has...

Akso Health Group recently announced its full year financial results for the period ended March 31, 2025, reporting sales of US$14.78 million and a net loss of US$134.98 million, alongside a basic and diluted loss per share of US$0.48. In addition, the company’s auditor expressed doubt about Akso Health Group’s ability to continue as a going concern in its latest annual filing, highlighting financial sustainability risks despite the growth in reported revenue. We’ll examine what the...

If you are weighing whether to jump into Royalty Pharma or considering if it is time to take some profits, you are not alone. This stock has become a topic of lively debate, especially as its recent run has caught the attention of both cautious and opportunistic investors. Over the past year, Royalty Pharma has delivered a total return of over 34%. What really stands out is its nearly 41% surge year-to-date. While its five-year numbers are barely in the red, the short-term momentum is...